Maintenance Lynparza Tablets Approved in Ovarian Cancer: Lynparza tablets (olaparib) tablets were granted FDA approval as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
According to the article, "...maintenance treatment with Lynparza showed a 70% reduction in the risk of progression or death compared with placebo for patients with platinum-sensitive, relapse, BRCA-mutant ovarian cancer. In Study 19, the risk of progression or death was reduced by 65%...regardless of BRCA status."
By the way, the article also stated that Lynparza tablets and capsules are not interchangeable and that the capsules are being phased out of the US. Apparently, it will only be available through the Lynparza Specialty Pharmacy Network.
In October 2012, a dream was realized for two dynamic ovarian cancer survivors: Anne Tonachel and Robin Bray. Their dream was to provide a restorative retreat for other ovarian cancer survivors in the northeast. When the amazing Kennedy family of Camp Kieve and The Kennedy Learning Center provided the retreat space (in honor of a family member with ovarian cancer), this restorative retreat was born.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment